Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of RO7771950 combined with trastuzumab and capecitabine compared to tucatinib with trastuzumab and capecitabine in people with locally advanced or metastatic HER2-positive breast cancer. This study includes patients with or without brain metastases and aims to provide new insights into treatments for this serious condition. The trial is a randomized, open-label study sponsored by Hoffmann-La Roche and involves multiple centers. Participants will be assigned to one of three groups two groups receive different doses of RO7771950 orally twice a day along with trastuzumab and capecitabine, while the third group receives tucatinib orally twice a day with the same combination of trastuzumab and capecitabine. Trastuzumab is given either intravenously or subcutaneously according to local guidelines, and capecitabine is taken orally twice daily. The study includes two parts and is designed to adapt as it progresses to ensure the best evaluation of treatments. During the trial, participants will be closely monitored through various assessments including imaging to measure tumor progression, quality of life evaluations, and safety checks such as heart function tests and monitoring of side effects. The main measure of success is progression-free survival over about 35 months. Other outcomes include overall survival, response rates, and symptom changes, with follow-ups continuing up to about 53 months. Participants will have regular visits for treatment and evaluations throughout the study period.